NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy tested for Tough-to-Treat lung cancer
Disease control OngoingThis study is testing whether adding a new drug called tiragolumab to two existing cancer drugs (atezolizumab and bevacizumab) can help control advanced non-squamous lung cancer that has worsened after prior treatment. It will enroll about 29 adults whose cancer has specific gene…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
AI designs custom vaccines to fight lung cancer
Disease control ENROLLING_BY_INVITATIONThis early-stage study is testing a personalized vaccine, Microlyvaq™, for people with advanced non-small cell lung cancer (NSCLC). The vaccine is custom-made for each patient using AI to analyze their specific tumor. It is given alongside standard chemotherapy and immunotherapy …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New hope for Tough-to-Treat lung cancer: major trial tests promising drug combo
Disease control OngoingThis study is for people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) where standard targeted pills have stopped working. It compares a new drug, AK112, combined with two common chemotherapy drugs against the same chemotherapy with a placebo. The …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New hope for Tough-to-Treat lung cancer: major trial tests promising drug combo
Disease control OngoingThis study is for adults with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) where standard targeted pills have stopped working. It aims to see if adding a new drug called AK112 to standard chemotherapy helps control the cancer better and helps people li…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC